NASDAQ:MRVI Maravai LifeSciences (MRVI) Stock Price, News & Analysis $2.07 +0.04 (+1.97%) Closing price 05/2/2025 04:00 PM EasternExtended Trading$2.06 0.00 (-0.24%) As of 05/2/2025 07:35 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock About Maravai LifeSciences Stock (NASDAQ:MRVI) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Maravai LifeSciences alerts:Sign Up Key Stats Today's Range$2.02▼$2.1250-Day Range$1.72▼$3.2552-Week Range$1.67▼$11.56Volume1.60 million shsAverage Volume2.36 million shsMarket Capitalization$526.48 millionP/E RatioN/ADividend YieldN/APrice Target$6.34Consensus RatingHold Company OverviewMaravai LifeSciences Holdings, Inc., a life sciences company, provides products to enable the development of drug therapies, diagnostics, novel vaccines, and support research on human diseases worldwide. The company's products address the key phases of biopharmaceutical development and include nucleic acids for diagnostic and therapeutic applications, antibody-based products to detect impurities during the production of biopharmaceutical products, and products to detect the expression of proteins in tissues of various species. It operates in two segments, Nucleic Acid Production and Biologics Safety Testing. The Nucleic Acid Production segment manufactures and sells products for use in the fields of gene therapy, vaccines, nucleoside chemistry, oligonucleotide therapy, and molecular diagnostics, including reagents used in the chemical synthesis, modification, labelling, and purification of deoxyribonucleic acid (DNA) and ribonucleic acid (RNA). This segment also offers messenger RNA, oligonucleotides, and oligonucleotide building blocks, as well as custom enzyme development and manufacturing and CleanCap capping technology. The Biologics Safety Testing segment sells analytical products for use in biologic manufacturing process development, including custom product-specific development antibody, and assay development services. This segment also provides HCP ELISA kits, other bioprocess impurity and contaminant ELISA kits, ancillary reagents, viral clearance prediction kits, and custom services. The company serves biopharmaceutical companies, and other biopharmaceutical and life sciences research companies; and academic research institutions and in vitro diagnostics companies. The company was incorporated in 2020 and is headquartered in San Diego, California.Read More… Maravai LifeSciences Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks81st Percentile Overall ScoreMRVI MarketRank™: Maravai LifeSciences scored higher than 81% of companies evaluated by MarketBeat, and ranked 88th out of 916 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion4.1 / 5Analyst RatingHold Consensus RatingMaravai LifeSciences has received a consensus rating of Hold. The company's average rating score is 2.18, and is based on 3 buy ratings, 7 hold ratings, and 1 sell rating.Amount of Analyst CoverageMaravai LifeSciences has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Maravai LifeSciences' stock forecast and price target. Earnings and Valuation1.3 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Maravai LifeSciences are expected to grow in the coming year, from ($0.24) to ($0.20) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Maravai LifeSciences is -1.26, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Maravai LifeSciences is -1.26, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioMaravai LifeSciences has a P/B Ratio of 0.66. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.Read more about Maravai LifeSciences' valuation and earnings. Short Interest1.0 / 5Short Interest LevelBearish Percentage of Shares Shorted5.56% of the float of Maravai LifeSciences has been sold short.Short Interest Ratio / Days to CoverMaravai LifeSciences has a short interest ratio ("days to cover") of 4.2.Change versus previous monthShort interest in Maravai LifeSciences has recently increased by 6.25%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldMaravai LifeSciences does not currently pay a dividend.Dividend GrowthMaravai LifeSciences does not have a long track record of dividend growth. Sustainability and ESG4.4 / 5Environmental Score-1.23 Percentage of Shares Shorted5.56% of the float of Maravai LifeSciences has been sold short.Short Interest Ratio / Days to CoverMaravai LifeSciences has a short interest ratio ("days to cover") of 4.2.Change versus previous monthShort interest in Maravai LifeSciences has recently increased by 6.25%, indicating that investor sentiment is decreasing significantly. News and Social Media1.7 / 5News Sentiment0.08 News SentimentMaravai LifeSciences has a news sentiment score of 0.08. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.73 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 27 news articles for Maravai LifeSciences this week, compared to 10 articles on an average week. Company Ownership0.8 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Maravai LifeSciences insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 0.63% of the stock of Maravai LifeSciences is held by insiders.Percentage Held by Institutions50.25% of the stock of Maravai LifeSciences is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Maravai LifeSciences' insider trading history. Receive MRVI Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Maravai LifeSciences and its competitors with MarketBeat's FREE daily newsletter. Email Address MRVI Stock News HeadlinesMaravai LifeSciences (MRVI) Reports Weak Q4, Faces Investor Class Action – Hagens BermanMay 3 at 9:17 AM | globenewswire.comLevi & Korsinsky Reminds Maravai LifeSciences Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of May 5, 2025 – MRVIMay 2 at 1:59 PM | globenewswire.comWarning: “DOGE Collapse” imminentElon Strikes Back You may already sense that the tide is turning against Elon Musk and DOGE. Just this week, President Trump promised to buy a Tesla to help support Musk in the face of a boycott against his company. But according to one research group, with connections to the Pentagon and the U.S. government, Elon's preparing to strike back in a much bigger way in the days ahead.May 4, 2025 | Altimetry (Ad)Levi & Korsinsky Reminds Maravai LifeSciences Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of May 5, 2025 - MRVIMay 2 at 5:45 AM | prnewswire.comMaravai LifeSciences (MRVI) Reports Weak Q4, Faces Investor Class Action – Hagens BermanMay 1 at 3:45 PM | globenewswire.comThe Gross Law Firm Notifies Shareholders of Maravai LifeSciences Holdings, Inc.(MRVI) of a Class Action Lawsuit and an Upcoming DeadlineMay 1 at 12:52 PM | globenewswire.comMaravai LifeSciences To Host Earnings Conference Call on Monday, May 12, 2025May 1 at 7:30 AM | globenewswire.comLost Money on Maravai LifeSciences Holdings, Inc.(MRVI)? Join Class Action Suit Seeking Recovery - Contact The Gross Law FirmMay 1 at 5:45 AM | prnewswire.comSee More Headlines MRVI Stock Analysis - Frequently Asked Questions How have MRVI shares performed this year? Maravai LifeSciences' stock was trading at $5.45 at the beginning of 2025. Since then, MRVI stock has decreased by 62.0% and is now trading at $2.07. View the best growth stocks for 2025 here. How were Maravai LifeSciences' earnings last quarter? Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI) posted its earnings results on Thursday, November, 7th. The company reported ($0.09) EPS for the quarter, missing analysts' consensus estimates of $0.00 by $0.09. The firm had revenue of $65.20 million for the quarter, compared to the consensus estimate of $67.58 million. Maravai LifeSciences had a negative net margin of 81.13% and a negative trailing twelve-month return on equity of 6.61%. Read the conference call transcript. When did Maravai LifeSciences IPO? Maravai LifeSciences (MRVI) raised $1.3 billion in an initial public offering (IPO) on Friday, November 20th 2020. The company issued 50,000,000 shares at a price of $24.00-$27.00 per share. Morgan Stanley, Jefferies and Goldman Sachs acted as the underwriters for the IPO and BofA Securities, Credit Suisse, UBS Investment Bank, Baird, William Blair, Stifel, Keybanc Securities, Academy Securities, Loop Capital Markets, Penserra Securities and Tigress Financial Partners were co-managers. Who are Maravai LifeSciences' major shareholders? Top institutional shareholders of Maravai LifeSciences include SG Americas Securities LLC (0.27%), Bank of New York Mellon Corp (0.12%), Massachusetts Financial Services Co. MA (0.10%) and Rhumbline Advisers (0.06%). Insiders that own company stock include Gtcr Investment Xi Llc, Carl Hull and Kurt Oreshack. View institutional ownership trends. How do I buy shares of Maravai LifeSciences? Shares of MRVI stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Maravai LifeSciences own? Based on aggregate information from My MarketBeat watchlists, some other companies that Maravai LifeSciences investors own include Waste Connections (WCN), American Water Works (AWK), The RMR Group (RMR), DiamondRock Hospitality (DRH), AUO (AUOTY), iShares Micro-Cap ETF (IWC) and Triple Flag Precious Metals (TFPM). Company Calendar Last Earnings11/07/2024Today5/04/2025Next Earnings (Estimated)5/12/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:MRVI CIK1823239 Webwww.maravai.com Phone858-546-0004FaxN/AEmployees610Year FoundedN/APrice Target and Rating Average Stock Price Target$6.34 High Stock Price Target$13.00 Low Stock Price Target$2.50 Potential Upside/Downside+206.5%Consensus RatingHold Rating Score (0-4)2.18 Research Coverage11 Analysts Profitability EPS (Most Recent Fiscal Year)($1.02) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-119,030,000.00 Net Margins-81.13% Pretax Margin159.33% Return on Equity-6.61% Return on Assets-3.45% Debt Debt-to-Equity Ratio0.89 Current Ratio10.74 Quick Ratio9.94 Sales & Book Value Annual Sales$259.19 million Price / Sales2.03 Cash Flow$0.05 per share Price / Cash Flow41.71 Book Value$3.14 per share Price / Book0.66Miscellaneous Outstanding Shares254,336,000Free Float250,937,000Market Cap$526.48 million OptionableOptionable Beta0.18 7 Stocks That Could Be Bigger Than Tesla, Nvidia, and GoogleLooking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.Get This Free Report This page (NASDAQ:MRVI) was last updated on 5/4/2025 by MarketBeat.com Staff From Our PartnersWarning: “DOGE Collapse” imminentElon Strikes Back You may already sense that the tide is turning against Elon Musk and DOGE. Just this week...Altimetry | SponsoredShocking AI play that’s beats Nvidia by a country mileYou’ve seen the headlines about Nvidia. Now Tim Sykes is sounding the alarm — because what CEO Jensen Huang is...Timothy Sykes | SponsoredTrump to redistribute trillions of dollars Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredTrump to solve American wealth loss?Is President Trump’s Executive Order 14179… A secret way to restore wealth for good citizens? If you’ve ...Paradigm Press | SponsoredWill May start the next "Great Depression?"You probably haven't heard about this yet... But this could be the biggest wealth building opportunity of t...Behind the Markets | Sponsored🥾⛏️👷♂️ What I Learned From Numerous Mine Visits...Twenty years ago, I made a decision that changed my life. Instead of sitting behind a desk analyzing mining...Golden Portfolio | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowThe July 23rd Crypto Trigger Could Mark the Beginning of Bitcoin’s Next Big Move Bitcoin’s early 2024 ETF r...Crypto Swap Profits | SponsoredHere’s How to Claim Your Stake in Elon’s Private Company, xAIEven though xAI is a private company, tech legend and angel investor Jeff Brown found a way for everyday folks...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Maravai LifeSciences Holdings, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Maravai LifeSciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.